Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pulmonary exacerbations in cystic fibrosis and bronchiectasis.

Literature DB >> 17387213

Pulmonary exacerbations in cystic fibrosis and bronchiectasis.

J S Elborn, S C Bell.

Abstract

Entities: Disease

Mesh：

Year: 2007 PMID： 17387213 PMCID： PMC2092464 DOI： 10.1136/thx.2006.065664

Source DB: PubMed Journal: Thorax ISSN： 0040-6376 Impact factor: 9.139

× No keyword cloud information.

21 in total

1. An investigation into causative factors in patients with bronchiectasis.

Authors: M C Pasteur; S M Helliwell; S J Houghton; S C Webb; J E Foweraker; R A Coulden; C D Flower; D Bilton; M T Keogan
Journal: Am J Respir Crit Care Med Date: 2000-10 Impact factor: 21.405

2. Clinical, laboratory findings and microbiologic characterization of bronchiectasis in Thai patients.

Authors: Apirak Palwatwichai; Chutima Chaoprasong; Anan Vattanathum; Adisorn Wongsa; Anon Jatakanon
Journal: Respirology Date: 2002-03 Impact factor: 6.424

3. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis.

Authors: Pedro A Piedra; Stanley G Cron; Alan Jewell; Nicole Hamblett; Ruth McBride; Melisa A Palacio; Richard Ginsberg; Christopher M Oermann; Peter W Hiatt
Journal: Vaccine Date: 2003-06-02 Impact factor: 3.641

4. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis.

Authors: J Angrill; C Agustí; R De Celis; X Filella; A Rañó; M Elena; J P De La Bellacasa; A Xaubet; A Torres
Journal: Am J Respir Crit Care Med Date: 2001-11-01 Impact factor: 21.405

5. Validation of the Hong Kong Chinese version of the St. George Respiratory Questionnaire in patients with bronchiectasis.

Authors: Shelley L Chan; Moira M Chan-Yeung; Gaik C Ooi; Cindy L Lam; Tung F Cheung; Wah K Lam; Kenneth W Tsang
Journal: Chest Date: 2002-12 Impact factor: 9.410

6. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.

Authors: J M Quan; H A Tiddens; J P Sy; S G McKenzie; M D Montgomery; P J Robinson; M E Wohl; M W Konstan
Journal: J Pediatr Date: 2001-12 Impact factor: 4.406

7. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

Authors: J Wolter; S Seeney; S Bell; S Bowler; P Masel; J McCormack
Journal: Thorax Date: 2002-03 Impact factor: 9.139

8. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period.

Authors: P L Shah; S Conway; S F Scott; M Rainisio; M Wildman; D Stableforth; M E Hodson
Journal: Respiration Date: 2001 Impact factor: 3.580

9. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

Authors: Lisa Saiman; Bruce C Marshall; Nicole Mayer-Hamblett; Jane L Burns; Alexandra L Quittner; Debra A Cibene; Sarah Coquillette; Ann Yunker Fieberg; Frank J Accurso; Preston W Campbell
Journal: JAMA Date: 2003-10-01 Impact factor: 56.272

Pulmonary exacerbations in cystic fibrosis and bronchiectasis.

1. An investigation into causative factors in patients with bronchiectasis.

2. Clinical, laboratory findings and microbiologic characterization of bronchiectasis in Thai patients.

3. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis.

4. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis.

5. Validation of the Hong Kong Chinese version of the St. George Respiratory Questionnaire in patients with bronchiectasis.

6. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.

7. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

8. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period.

9. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

Review 10. Exacerbations in cystic fibrosis: 2 . prevention.

1. The Cystic Fibrosis Symptom Progression Survey (CF-SPS) in Arabic: A Tool for Monitoring Patient's Symptoms.

2. Microstructural alterations of sputum in cystic fibrosis lung disease.

Review 3. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.

Review 4. Airway clearance techniques for bronchiectasis.

5. Pulmonary Function and Hospital Admission in Patients with Cystic Fibrosis Based on Household Second-Hand Smoking.

Review 6. Impact of Pseudomonas aeruginosa Infection on Patients with Chronic Inflammatory Airway Diseases.

7. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.

8. Epidemiology and natural history of Pseudomonas aeruginosa airway infections in non-cystic fibrosis bronchiectasis.